Company news

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) news

Every Processa Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) news

Press releases & updates

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEM...

Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Processa Pharmaceuticals Provides Portfolio and Business Update

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Can...

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Processa Pharmaceuticals Provides Product Pipeline and Financial Update

Processa Pharmaceuticals Announces Positive Preclinical Data for NGC-Iri

Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer

Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap i...

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Result...

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Ov...

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Onc...

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies

Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insider...

Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial

Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update

Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial

Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs

Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board

Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update...

Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis ...